TY - JOUR
T1 - Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort
AU - Nakagawa, Yu
AU - Sasaki, Hikaru
AU - Ohara, Kentaro
AU - Ezaki, Taketo
AU - Toda, Masahiro
AU - Ohira, Takayuki
AU - Kawase, Takeshi
AU - Yoshida, Kazunari
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/10
Y1 - 2017/10
N2 - Objective The purpose of this study was to clarify the clinical and molecular characteristics associated with long-term survival in patients with glioblastoma. Methods We analyzed the characteristics of 96 glioblastoma patients. Long-term survivors (LTSs) were classified into moderate LTSs (mLTSs), who survived >3 years, and LTSs, who survived >5 years, and compared with short-term survivors (STSs). Clinical and molecular factors were investigated. Results Younger age, better recursive partitioning analysis class, lack of subventricular zone (SVZ) involvement, promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene, and loss of 19q were associated with mLTSs as compared with STSs. After adjustment for these factors, younger age and MGMT methylation remained independently associated with mLTSs. Younger age, better recursive partitioning analysis class, lack of SVZ involvement, and loss of 19q were associated with LTSs as compared with STSs. After adjustment, younger age and better preoperative Karnofsky performance scale (KPS) score remained independently associated with LTSs. Kaplan-Meier analyses revealed that younger age (<50 years), better preoperative KPS score (≥70), lack of SVZ involvement, and loss of 19q were associated with longer overall survival. In the multivariate analysis, only age was significantly associated with overall survival. Conclusions Younger age and better preoperative KPS score were the characteristics associated with LTSs as compared with STSs. MGMT promoter methylation was associated with mLTSs, but not with LTSs. In addition, lack of SVZ involvement and loss of 19q might be prognostic for longer survival.
AB - Objective The purpose of this study was to clarify the clinical and molecular characteristics associated with long-term survival in patients with glioblastoma. Methods We analyzed the characteristics of 96 glioblastoma patients. Long-term survivors (LTSs) were classified into moderate LTSs (mLTSs), who survived >3 years, and LTSs, who survived >5 years, and compared with short-term survivors (STSs). Clinical and molecular factors were investigated. Results Younger age, better recursive partitioning analysis class, lack of subventricular zone (SVZ) involvement, promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene, and loss of 19q were associated with mLTSs as compared with STSs. After adjustment for these factors, younger age and MGMT methylation remained independently associated with mLTSs. Younger age, better recursive partitioning analysis class, lack of SVZ involvement, and loss of 19q were associated with LTSs as compared with STSs. After adjustment, younger age and better preoperative Karnofsky performance scale (KPS) score remained independently associated with LTSs. Kaplan-Meier analyses revealed that younger age (<50 years), better preoperative KPS score (≥70), lack of SVZ involvement, and loss of 19q were associated with longer overall survival. In the multivariate analysis, only age was significantly associated with overall survival. Conclusions Younger age and better preoperative KPS score were the characteristics associated with LTSs as compared with STSs. MGMT promoter methylation was associated with mLTSs, but not with LTSs. In addition, lack of SVZ involvement and loss of 19q might be prognostic for longer survival.
KW - Age
KW - Glioblastoma
KW - Long-term survival
KW - Loss of 19q
KW - MGMT
KW - Subventricular zone involvement
UR - http://www.scopus.com/inward/record.url?scp=85024475661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85024475661&partnerID=8YFLogxK
U2 - 10.1016/j.wneu.2017.06.126
DO - 10.1016/j.wneu.2017.06.126
M3 - Article
C2 - 28666913
AN - SCOPUS:85024475661
SN - 1878-8750
VL - 106
SP - 165
EP - 173
JO - World Neurosurgery
JF - World Neurosurgery
ER -